A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.
Geert D'HaensLaurent Peyrin BirouletDaniel J B MarksEdoardo LisiLia LiefaardAndrew BeatonNaren SrinivasanGerben BoumaNaveen PrasadRaymond CameronZeid KayaliRuth TarziStephen HanauerWilliam J SandbornPublished in: Alimentary pharmacology & therapeutics (2023)
Despite evidence of target cell depletion in blood, GSK2831781 failed to reduce inflammation in the colonic mucosa suggesting no pharmacological effect. The study was terminated early (NCT03893565).